Kai Eriksson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kai Eriksson has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Reetta Kälviäinen
4 shared publicationsJukka Peltola
2 shared publicationsMatti Koivikko
2 shared publicationsPirkko Nieminen
Department of Psychology, 33014 University of Tampere, Finland
2 shared publicationsA. -L. Kuusela
From the Pediatric Research Centre (Drs. Eriksson, Metsäranta, Koivikko), Medical School, University of Tampere and Tampere University Hospital, Department of Pediatrics, Pediatric Neurology Unit; Tampere School of Public Health (Drs. Huhtala, Auvinen), University of Tampere; Department of Pediatrics (Dr. Kuusela), Pediatric Intensive Care Unit, Tampere University Hospital, Tampere, Finland
1 shared publicationA.M Haapala
Department of Clinical Microbiology, Centre for Laboratory Medicine, Tampere University Hospital, Tampere, FIN-33521 Finland
1 shared publication
Latest Publications
- 15 May 2009
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 5 (6) , 695-701
Fosphenytoin
Fosphenytoin, phosphate ester pro-drug of phenytoin, was developed to overcome complications associated with parenteral phenytoin administration in treatment of acute symptomatic seizures, short-term prophylaxis and treatment of repetitive or prolonged seizures and status epilepticus.
- 15 May 2009
- Published by Informa Healthcare in Expert Opinion on Drug Metabolism & Toxicology
- Vol. 5 (6) , 695-701
Fosphenytoin
Fosphenytoin, phosphate ester pro-drug of phenytoin, was developed to overcome complications associated with parenteral phenytoin administration in treatment of acute symptomatic seizures, short-term prophylaxis and treatment of repetitive or prolonged seizures and status epilepticus.
- 1 November 2005
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 5 (6) , 777-783
Pharmacologic management of convulsive status epilepticus in childhood
The incidence of convulsive status epilepticus in children is approximately 20-50/100,000/year, and is an emergency requiring prompt medical intervention. Prolonged seizures lasting over 5 min are unlikely to stop spontaneously, and time-to-treatment influences treatment response. Prolonged seizures should thus be treated as early status epilepticus. Mortality and morbidity increase significantly with the length of ongoing seizure activity, especially after 60 min. Benzodiazepines remain the first-line drug therapy due to their rapid onset of action. Recent studies imply that buccal midazolam is more effective and easier to administer than rectal diazepam. Phenytoin/fosphenytoin and phenobarbital administered intravenously remain the second-line treatments of choice, whilst barbiturates and midazolam as intravenous anesthetics are used for third-line treatment. Electroencephalogram monitoring is essential to evaluate the electrophysiologic treatment response and depth of anesthesia, especially in refractory status epilepticus. In the future, more individualized protocols and pathways are needed in order to optimize treatment responses. Randomized clinical trials are needed to evaluate new treatment protocols, which should not only stop the seizures more effectively but also be safer and include some neuroprotective elements to halt the cascade of neuronal injury and minimize the risk for neurologic morbidity caused by the convulsive status epilepticus.
- 1 November 2005
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 5 (6) , 777-783
Pharmacologic management of convulsive status epilepticus in childhood
The incidence of convulsive status epilepticus in children is approximately 20-50/100,000/year, and is an emergency requiring prompt medical intervention. Prolonged seizures lasting over 5 min are unlikely to stop spontaneously, and time-to-treatment influences treatment response. Prolonged seizures should thus be treated as early status epilepticus. Mortality and morbidity increase significantly with the length of ongoing seizure activity, especially after 60 min. Benzodiazepines remain the first-line drug therapy due to their rapid onset of action. Recent studies imply that buccal midazolam is more effective and easier to administer than rectal diazepam. Phenytoin/fosphenytoin and phenobarbital administered intravenously remain the second-line treatments of choice, whilst barbiturates and midazolam as intravenous anesthetics are used for third-line treatment. Electroencephalogram monitoring is essential to evaluate the electrophysiologic treatment response and depth of anesthesia, especially in refractory status epilepticus. In the future, more individualized protocols and pathways are needed in order to optimize treatment responses. Randomized clinical trials are needed to evaluate new treatment protocols, which should not only stop the seizures more effectively but also be safer and include some neuroprotective elements to halt the cascade of neuronal injury and minimize the risk for neurologic morbidity caused by the convulsive status epilepticus.
- 25 October 2005
- Published by Wolters Kluwer Health in Neurology
- Vol. 65 (8) , 1316-1318
Treatment delay and the risk of prolonged status epilepticus
Factors contributing to the duration of a single convulsive seizure > 5 minutes were analyzed in 157 children. The medically treated episodes were compared with seizure episodes resolving without treatment (n = 27). Major differences were in age (p = 0.016) and etiology (p = 0.003), and the association between treatment delay and response became significant after 30 minutes when this was analyzed as a single variable (p = 0.003) in Cox regression analysis.
- 25 October 2005
- Published by Wolters Kluwer Health in Neurology
- Vol. 65 (8) , 1316-1318
Treatment delay and the risk of prolonged status epilepticus
Factors contributing to the duration of a single convulsive seizure > 5 minutes were analyzed in 157 children. The medically treated episodes were compared with seizure episodes resolving without treatment (n = 27). Major differences were in age (p = 0.016) and etiology (p = 0.003), and the association between treatment delay and response became significant after 30 minutes when this was analyzed as a single variable (p = 0.003) in Cox regression analysis.
- 1 July 2005
- Published by Elsevier in Epilepsy Research
- Vol. 65 (3) , 189-200
Children exposed to valproate in utero—Population based evaluation of risks and confounding factors for long-term neurocognitive development
- 1 July 2005
- Published by Elsevier in Epilepsy Research
- Vol. 65 (3) , 189-200
Children exposed to valproate in utero—Population based evaluation of risks and confounding factors for long-term neurocognitive development
- 1 January 2005
- Vol. 121 (5) , 505-12
[From treating the seizures to the treatment of epilepsy].
- Open Access
- 1 January 2004
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 46 (1) , 4-8
Outcome after prolonged convulsive seizures in 186 children: low morbidity, no mortality
Prolonged convulsive seizures are a common neurological emergency and a potential cause of neuronal damage and functional sequelae. We explored the role of seizure duration and various background factors for neurological sequelae in children with prolonged convulsive seizures. The population‐base of this study was all children (age < 16 years) who had been admitted to the Tampere University Hospital, Finland between 1993 and 1999 with convulsive seizures lasting more than 5 minutes. Patients were followed up individually (mean length of follow‐up 2 years 1 month, range 0 to 7 years 8 months). All available data on the prolonged seizure episodes and clinical follow‐up were analyzed retrospectively by a detailed review of all medical charts and records. In 186 children (94 males, 92 females; mean age 4 years 5 months, SD 3 years 10 months, range 1 month to 15 years 4 months) there were 279 separate convulsive seizure episodes lasting over 5 minutes, yielding an annual incidence of 47.5 out of every 100000 episodes. Seizure aetiology was idiopathic in 26.2% of episodes, febrile in 41.9%, remote symptomatic in 28%, and acute symptomatic in 3.9% of episodes. Mean duration of all seizure episodes was 42.5 minutes (SD 46.1 minutes) and was significantly correlated with the aetiology: shortest in the febrile group (mean 35.4 minutes) and longest in the acute symptomatic group (mean 88.6 minutes; p < 0.001). There was no mortality related directly to these acute seizure episodes. The most common sequela was an onset of epilepsy in 40 children (22%). Permanent neurological sequelae were noted in only four patients (2.2%; mean seizure duration 16 minutes) and non‐permanent sequelae in six patients (3.2%; mean seizure duration 38 minutes). Neurological sequelae of prolonged convulsive seizures in children are rare and are related to aetiological factors rather than the duration of a single seizure. The role of acute seizures in the evolution of epilepsy in children remains obscure.
- 1 January 2004
- Published by Wiley in Developmental Medicine & Child Neurology
- Vol. 46 (1) , 4-8
Open AccessOutcome after prolonged convulsive seizures in 186 children: low morbidity, no mortality
Prolonged convulsive seizures are a common neurological emergency and a potential cause of neuronal damage and functional sequelae. We explored the role of seizure duration and various background factors for neurological sequelae in children with prolonged convulsive seizures. The population‐base of this study was all children (age < 16 years) who had been admitted to the Tampere University Hospital, Finland between 1993 and 1999 with convulsive seizures lasting more than 5 minutes. Patients were followed up individually (mean length of follow‐up 2 years 1 month, range 0 to 7 years 8 months). All available data on the prolonged seizure episodes and clinical follow‐up were analyzed retrospectively by a detailed review of all medical charts and records. In 186 children (94 males, 92 females; mean age 4 years 5 months, SD 3 years 10 months, range 1 month to 15 years 4 months) there were 279 separate convulsive seizure episodes lasting over 5 minutes, yielding an annual incidence of 47.5 out of every 100000 episodes. Seizure aetiology was idiopathic in 26.2% of episodes, febrile in 41.9%, remote symptomatic in 28%, and acute symptomatic in 3.9% of episodes. Mean duration of all seizure episodes was 42.5 minutes (SD 46.1 minutes) and was significantly correlated with the aetiology: shortest in the febrile group (mean 35.4 minutes) and longest in the acute symptomatic group (mean 88.6 minutes; p < 0.001). There was no mortality related directly to these acute seizure episodes. The most common sequela was an onset of epilepsy in 40 children (22%). Permanent neurological sequelae were noted in only four patients (2.2%; mean seizure duration 16 minutes) and non‐permanent sequelae in six patients (3.2%; mean seizure duration 38 minutes). Neurological sequelae of prolonged convulsive seizures in children are rare and are related to aetiological factors rather than the duration of a single seizure. The role of acute seizures in the evolution of epilepsy in children remains obscure.
- 1 June 2003
- Published by Elsevier in Brain and Development
- Vol. 25 (4) , 262-267
Visual agnosia in a child with non-lesional occipito-temporal CSWS
- 1 June 2003
- Published by Elsevier in Brain and Development
- Vol. 25 (4) , 262-267
Visual agnosia in a child with non-lesional occipito-temporal CSWS
- 1 August 2001
- Published by Elsevier in Epilepsy Research
- Vol. 46 (2) , 129-137
High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases
- 1 August 2001
- Published by Elsevier in Epilepsy Research
- Vol. 46 (2) , 129-137
High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases
- Open Access
- 1 May 2001
- Published by BMJ in Archives of Disease in Childhood
- Vol. 84 (5) , 434-435
Acute neurology and neurophysiology of haemolytic-uraemic syndrome
Involvement of the central nervous system (CNS) is found in around 30% of children with haemolytic–uraemic syndrome (HUS). This complication is the single most common cause of mortality and also a major contributor to the morbidity associated with HUS. We reviewed 22 children with HUS and acute CNS involvement. Both global and focal derangements occurred, and in survivors, early regional EEG abnormalities—especially those in the occipital and temporal areas—were prognostically useful.
- 1 May 2001
- Published by BMJ in Archives of Disease in Childhood
- Vol. 84 (5) , 434-435
Open AccessAcute neurology and neurophysiology of haemolytic-uraemic syndrome
Involvement of the central nervous system (CNS) is found in around 30% of children with haemolytic–uraemic syndrome (HUS). This complication is the single most common cause of mortality and also a major contributor to the morbidity associated with HUS. We reviewed 22 children with HUS and acute CNS involvement. Both global and focal derangements occurred, and in survivors, early regional EEG abnormalities—especially those in the occipital and temporal areas—were prognostically useful.